Advicenne: 2026 Financial Calendar

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2026 financial communication calendar.

*: subject to change. End of trading

About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120881430/en/

Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: [email protected]

Maarc
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: [email protected]

Source: Advicenne

You May Also Be Interested In

• Caspian Acquires Trade-IQ, Expanding from Duty Recovery into Full-Lifecycle Trade Advisory
• Express Survey Finds AI's Real Workplace Debate Is No Longer Whether to Use It -- It's Where to Stop
• ARCYN Defense Announces Investment Round to Accelerate Development of Next-Generation Hypersonic Kinetic Counter-UAS System